comparemela.com

Latest Breaking News On - Len liptak - Page 8 : comparemela.com

ProSomnus to Present New Data on Oral Appliance Efficacy

ProSomnus will present new data demonstrating the efficacy of its precision oral appliances for OSA at upcoming medical conferences.

Region flamandeUnited statesRio de janeiroEstado do rioJohn remmersErin moscaOlivier vandervekenLen liptakEdward sallMarc braemMarijke dieltjensInternational surgical sleep societyAmerican college of chest physiciansProsomnus incAmerican academy of otolaryngologyAntwerp university hospital

Preliminary Data Suggest Precision OAT is Non-Inferior to CPAP

The First Line Obstructive Sleep Apnea Treatment study is on track to achieve all endpoints, according to Prosomnus.

Region flamandeRio de janeiroEstado do rioLen liptakOlivier vandervekenProsomnus incWorld sleep congressAntwerp university hospitalFirst line obstructive sleep apnea treatment

ProSomnus Oral Appliances Supported by Clinical Data in Q2

ProSomnus Inc announced second-quarter business highlights, showcasing progress for its precision oral appliances.

United statesLen liptakProsomnus incFront line obstructive sleep apnea treatmentSevere obstructive sleep apnea study

ProSomnus Reports Record Second Quarter 2023 Top-Line

PLEASANTON, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) ProSomnus, Inc. (“the Company” or “ProSomnus”) (NASDAQ: OSA), a leading CPAP alternative for the.

United statesLen liptakSean leousMike cavanaughBrian dowProsomnus incDrug administrationCompany or prosomnusExchange commissionSecurities exchangeObstructive sleep apneaFront line obstructive sleep apnea treatmentSevere obstructive sleep apnea studyChief executiveSecond quarterSomnus chief executive officer

ProSomnus Reports Record Second Quarter 2023 Top-Line Financial Results

PLEASANTON, Calif., Aug. 03, 2023 ProSomnus, Inc. , a leading CPAP alternative for the treatment of Obstructive Sleep Apnea , today announced financial results for the second quarter.

United statesSean leousLen liptakMike cavanaughBrian dowSecurities exchangeExchange commissionCompany or prosomnusDrug administrationProsomnus incObstructive sleep apneaFront line obstructive sleep apnea treatmentSevere obstructive sleep apnea studyChief executiveSecond quarterSomnus chief executive officer

vimarsana © 2020. All Rights Reserved.